It is also unclear how much daily imported energy China is using right away, and how much is being funnelled into its oil reserves, says Hansen. The sheer volume, he adds, still serves as a "substantial buffer" for times of disruption.
It is also unclear how much daily imported energy China is using right away, and how much is being funnelled into its oil reserves, says Hansen. The sheer volume, he adds, still serves as a "substantial buffer" for times of disruption.
Diabetes drugs could prevent anxiety and depression from worsening, according to research. Type 2 diabetes affects more than 800 million people globally and research shows that those with the condition are about twice as likely to have depression as the wider population. GLP-1 receptor agonists such as semaglutide are commonly prescribed for diabetes and obesity. While studies have found other hea...
Diabetes drugs could prevent anxiety and depression from worsening, according to research. Type 2 diabetes affects more than 800 million people globally and research shows that those with the condition are about twice as likely to have depression as the wider population. GLP-1 receptor agonists such as semaglutide are commonly prescribed for diabetes and obesity. While studies have found other health benefits beyond weight loss and better blood sugar levels, the medications’ effects on mental health have been unclear. International researchers examined Swedish health records of almost 95,000 people with a diagnosis of depression or anxiety who were also taking various diabetes medications between 2009 and 2022. The study compared periods when patients were taking GLP1s, or other second-line diabetes medications, with when they were not taking them. Worsening mental health was assessed through data on psychiatric hospital admissions, sick leave from work due to mental health reasons, hospitalisation owing to self-harm and death by suicide. Published in the Lancet Psychiatry, the research also examined data on new diagnoses of anxiety and depression. The authors found that semaglutide, the active ingredient in the drugs Ozempic for diabetes and Wegovy for weight loss, as well as liraglutide (Saxenda) were associated with a lower risk of worsening mental illness in those with anxiety and depression. Semaglutide had a 42% lower risk of worsening mental health, while liraglutide was linked to an 18% lower risk. Other GLP-1 drugs, including exenatide and dulaglutide, did not show the same benefit. Semaglutide was associated with a 44% lower risk of worsening depression, a 38% lower risk of worsening anxiety and a 47% lower risk of worsening substance use disorder. “For anxiety and depression that co-occur with diabetes and obesity, semaglutide and, to a lesser extent, liraglutide might be useful dually effective therapeutic options,” the authors concluded. Dr Markku Lähte...
Swedish people with depression and anxiety who took Novo Nordisk A/S ’s blockbuster shots Ozempic and Wegovy were less likely to see their mental health get worse, the latest data to suggest that popular diabetes and obesity drugs could also have a broader impact on well-being. Semaglutide, the main ingredient in both drugs, was linked to a 44% lower risk of worsening depression, a 38% lower risk ...
Swedish people with depression and anxiety who took Novo Nordisk A/S ’s blockbuster shots Ozempic and Wegovy were less likely to see their mental health get worse, the latest data to suggest that popular diabetes and obesity drugs could also have a broader impact on well-being. Semaglutide, the main ingredient in both drugs, was linked to a 44% lower risk of worsening depression, a 38% lower risk of worsening anxiety and a 47% lower risk of worsening addiction, in results published in The Lancet Psychiatry journal. The researchers followed almost 95,000 people who had diabetes or obesity and a mental health diagnosis. The data was dramatic enough to warrant a clinical trial to establish whether Ozempic and Wegovy could help treat these disorders, the researchers said. The results come amid mounting evidence that GLP-1 receptor agonists — a class that also includes Eli Lilly & Co. ’s Zepbound — can have an impact on addiction, and they provide a counterpoint to earlier fears, now debunked , that the medicines could be linked to a higher rate of suicides. “Better mental health tends to follow from better physical health, and since the 1880s we have known that diabetes is associated with depression,” David Nutt , head of the Centre for Neuropsychopharmacology at Imperial College London, said in comments circulated by the Science Media Centre. It’s unlikely that using GLP-1 drugs alone as treatments for depression or anxiety will work, he said.
The Federal Bureau of Investigation has started buying location data on Americans, Kash Patel, FBI director, said under oath at the Senate intelligence committee worldwide threats hearing on Wednesday. Patel’s admission came in response to a question from the senator Ron Wyden, an Oregon Democrat who is a longtime opponent of the warrantless surveillance of Americans. Wyden told Patel that his pre...
The Federal Bureau of Investigation has started buying location data on Americans, Kash Patel, FBI director, said under oath at the Senate intelligence committee worldwide threats hearing on Wednesday. Patel’s admission came in response to a question from the senator Ron Wyden, an Oregon Democrat who is a longtime opponent of the warrantless surveillance of Americans. Wyden told Patel that his predecessor, Christopher Wray, testified in 2023 that the FBI did not at that time purchase location data derived from internet advertising, although he acknowledged that it had done so in the past. “Is that the case still?” Wyden asked. “And if so, can you commit this morning to not buying Americans’ location data?” “We do purchase commercially available information that’s consistent with the constitution and the laws under the Electronic Communications Privacy Act, and it has led to some valuable intelligence for us,” Patel responded. “So you’re saying that the agency will buy Americans’ location data,” Wyden said. “I believe that that’s what you’ve said in kind of intelligence lingo. And I just want to say as we start this debate, doing that without a warrant is an outrageous end run around the fourth amendment. It’s particularly dangerous given the use of artificial intelligence to comb through massive amounts of private information. “This is exhibit A for why Congress needs to pass our bipartisan, bicameral bill, the Government Surveillance Reform act,” Wyden said, referring to legislation he is working to pass to rein in surveillance. While law enforcement must get a judge-authorized search warrant to obtain location data directly from telecom companies, government agencies have instead been able to buy such information from private data brokers. Wyden’s questioning of Patel on this issue was amplified on social media by Warren Davidson, a House Republican who introduced a bill mirroring Wyden’s Senate measure with the Democratic representative Zoe Lofgren. “This is a cl...
Key Points RWR charges nearly double the expense ratio of VNQ, but it's outperformed over the past five years. Both ETFs hold similar top REITs, though VNQ offers broader diversification with more holdings. Risk profiles are closely matched, with similar betas and max drawdowns. 10 stocks we like better than SPDR Series Trust - State Street SPDR Dow Jones REIT ETF › The Vanguard Real Estate ETF (N...
Key Points RWR charges nearly double the expense ratio of VNQ, but it's outperformed over the past five years. Both ETFs hold similar top REITs, though VNQ offers broader diversification with more holdings. Risk profiles are closely matched, with similar betas and max drawdowns. 10 stocks we like better than SPDR Series Trust - State Street SPDR Dow Jones REIT ETF › The Vanguard Real Estate ETF (NYSEMKT:VNQ) and the State Street SPDR Dow Jones REIT ETF (NYSEMKT:RWR) are both designed to give investors access to the U.S. real estate sector via publicly traded REITs. While their mandates are similar, this comparison highlights differences in expenses, size, diversification, and recent performance that may appeal to different types of real estate-focused investors. Snapshot (cost & size) Metric VNQ RWR Issuer Vanguard SPDR Expense ratio 0.13% 0.25% 1-yr return (as of March 18, 2026) 5.80% 9.57% Dividend yield 3.63% 3.44% Beta (5Y monthly) 1.15 1.12 AUM $69.6 billion $1.8 billion VNQ is more affordable on fees, charging a lower expense ratio than RWR. It also delivers a slightly higher dividend yield, which may appeal to those focused on building long-term income. Performance & risk comparison Metric VNQ RWR Max drawdown (5 y) -34.50% -32.56% Growth of $1,000 over 5 years $992 $1,076 RWR has posted a stronger total return over five years while also experiencing a slightly milder maximum drawdown. Both ETFs show similar risk levels based on beta, suggesting comparable volatility profiles. What's inside RWR seeks to mirror the Dow Jones U.S. Select REIT Capped Index and currently holds 98 U.S.-listed REITs, with a portfolio dominated by Prologis, Welltower, and Equinix. The fund is heavily concentrated in real estate and does not employ leverage, currency hedging, or ESG screens. Launched nearly 25 years ago, it offers investors a strong track record in real estate. VNQ tracks a broader real estate index, spreading its assets across 146 holdings. It offers similar top exp...
The company is making excellent progress ramping its industry-leading 1g DRAM and G9 NAND technology nodes. The 1g node is noted as the fastest ramp to mature yields in the company's history and is ramping volumes faster than all prior nodes. It is on track to become a majority of the company's DRAM bit mix by mid-calendar 2026. The company plans to increase EUV adoption at the next-generation 1d ...
The company is making excellent progress ramping its industry-leading 1g DRAM and G9 NAND technology nodes. The 1g node is noted as the fastest ramp to mature yields in the company's history and is ramping volumes faster than all prior nodes. It is on track to become a majority of the company's DRAM bit mix by mid-calendar 2026. The company plans to increase EUV adoption at the next-generation 1d DRAM node, utilizing the latest-generation EUV tools to optimize cleanroom space efficiency and patterning. In NAND, the G9 node also remains on track to constitute a majority of bits by mid-calendar 2026. The company also achieved a record mix of QLC bits in the quarter. Micron continues to work with customers on strategic customer agreements that differ from prior long-term agreements, providing multiyear commitments for improved visibility and stability. The company has signed its first five-year strategic customer agreement. The improved results and outlook are attributed to an increase in memory demand driven by AI, structural supply constraints, and the company's strong execution. The firm's memory and storage solutions are described as being at the heart of the AI revolution, with memory enabling longer context windows, deeper reasoning chains, and multi-agent orchestration. As AI evolves, compute architectures are expected to become more memory intensive, fundamentally recasting memory as a strategic asset. The company's revenue guidance for the fiscal third quarter exceeds the full-year revenue for every year in its history through fiscal 2024. For that upcoming quarter, Micron anticipates exceptional growth across revenue, gross margin, earnings per share, and free cash flow. Reflecting confidence in the sustained strength of the business, the Board approved a 30% increase in the quarterly dividend. According to a transcript from The Motley Fool, Micron Technology delivered an exceptional fiscal second quarter, with stellar records in revenue, gross margin, earnin...
"This legislation strengthens safeguards and restores clear limits on eligibility to protect vulnerable Albertans facing mental illness or living with disabilities," she said. "Those struggling with severe mental health challenges need treatment, compassion and support, not a path to end their life at what may be their lowest moment."
"This legislation strengthens safeguards and restores clear limits on eligibility to protect vulnerable Albertans facing mental illness or living with disabilities," she said. "Those struggling with severe mental health challenges need treatment, compassion and support, not a path to end their life at what may be their lowest moment."
Earnings Call Insights: Sera Prognostics (SERA) Q4 2025 Management View President and CEO Evguenia Lindgardt highlighted 2025 as a pivotal year, emphasizing, "2025 was a critical year for Sera, finalizing our PRIME publication to advance our evidence portfolio, setting up for commercial push in 2026, building our organization, ensuring we have capital to deploy in our commercialization efforts and...
Earnings Call Insights: Sera Prognostics (SERA) Q4 2025 Management View President and CEO Evguenia Lindgardt highlighted 2025 as a pivotal year, emphasizing, "2025 was a critical year for Sera, finalizing our PRIME publication to advance our evidence portfolio, setting up for commercial push in 2026, building our organization, ensuring we have capital to deploy in our commercialization efforts and laying groundwork for potential international expansion. Our goal was simple: to build the evidence, access and commercial infrastructure required to drive PreTRM adoption at scale." The company strengthened its leadership with the addition of Lee Anderson as Chief Commercial Officer and Dr. Tiffany Inglis as Chief Medical Officer. Lindgardt noted, "We exceeded our state engagement goals in 2025, expanding discussions to 13 states and met our goal of engaging in now 2 live partner programs." Anderson described a "region-first approach, pairing payer engagement with OB/GYN and maternal fetal medicine education, health system outreach and patient awareness to build local market density," with plans to expand active state discussions to 15–17 states and double payer engagements in 2026. The company also welcomed Adrienne Lugo as Head of Sales and Strategic Accounts. Chief Medical Officer Dr. Tiffany Inglis said, "Our medical affairs work in 2026 is focused on ensuring PRIME acts as a catalyst for consistent evidence-based practice," with priorities on risk identification, standardized pathways, and improved neonatal outcomes. Chief Financial Officer Austin Aerts reported, "Revenue for the quarter was $10,000 compared to $24,000 in the fourth quarter of 2024... Operating expenses for the quarter were $9 million, down from $9.4 million for the prior year period." He added, "We ended December 31, 2025, with $95.8 million in cash, cash equivalents and available-for-sale securities... we believe this capital will fund the company across significant adoption and commercial mileston...